---
title: "Common Pediatric Conditions"
order: 7
category: "Pediatrics"
---

# Common Pediatric Conditions

## Overview

Common pediatric conditions account for the majority of outpatient visits and represent conditions that general pediatricians and family physicians encounter regularly. These conditions span multiple organ systems and include both acute illnesses and chronic conditions requiring ongoing management. Understanding the evidence-based approach to diagnosis and management of these common conditions is essential for all healthcare providers caring for children.

**Key Concept**: While individually common conditions may seem straightforward, pediatric-specific considerations regarding dosing, differential diagnosis, and age-appropriate management require specialized knowledge to optimize outcomes and avoid complications.

### Categories
- **Respiratory**: Asthma, croup, bronchiolitis
- **Gastrointestinal**: Gastroenteritis, constipation, GERD
- **Dermatologic**: Atopic dermatitis, diaper dermatitis
- **Hematologic**: Anemia, sickle cell disease
- **Endocrine**: Type 1 diabetes, thyroid disorders
- **Neurologic**: Febrile seizures, headaches
- **Behavioral**: ADHD, autism spectrum disorder

## Respiratory Conditions

### Asthma

#### Overview
- **Most common chronic disease**: Of childhood
- **Prevalence**: 8-10% of children in the United States
- **Pathophysiology**: Chronic airway inflammation, hyperresponsiveness, reversible obstruction

#### Risk Factors
- **Genetics**: Family history of asthma or atopy
- **Environmental**: Allergens, smoke exposure, pollution
- **Infections**: Early respiratory infections (RSV, rhinovirus)
- **Obesity**: Increased risk and severity
- **Race/ethnicity**: Higher prevalence in African Americans, Puerto Ricans

#### Clinical Presentation

##### Symptoms
- **Wheezing**: Expiratory wheeze most common
- **Cough**: Dry, worse at night or with exercise
- **Dyspnea**: Shortness of breath
- **Chest tightness**: Described by older children
- **Exercise limitation**: Difficulty keeping up with peers
- **Nocturnal symptoms**: Sleep disruption

##### Triggers
- **Viral infections**: Most common trigger in young children
- **Exercise**: Exercise-induced bronchospasm
- **Allergens**: Dust mites, pets, pollen, mold
- **Irritants**: Smoke, strong odors, cold air
- **Weather changes**: Cold air, humidity

#### Diagnosis

##### Clinical Diagnosis (Young Children)
- **History**: Recurrent wheezing, cough, dyspnea
- **Physical exam**: Wheezing on auscultation (may be normal between episodes)
- **Response to therapy**: Trial of bronchodilator
- **Atopic features**: Eczema, allergic rhinitis, food allergies

##### Pulmonary Function Testing (>5 years)
- **Spirometry**: Decreased FEV1/FVC ratio
- **Reversibility**: ≥12% improvement in FEV1 after bronchodilator
- **Bronchoprovocation**: Methacholine or exercise challenge if spirometry normal
- **Peak flow monitoring**: Home monitoring for control assessment

#### Classification

##### Intermittent
- **Symptoms**: ≤2 days/week
- **Nighttime awakenings**: ≤2 times/month
- **SABA use**: ≤2 days/week
- **Interference**: None
- **Exacerbations**: 0-1/year requiring oral steroids
- **FEV1**: Normal (>80% predicted)

##### Mild Persistent
- **Symptoms**: >2 days/week but not daily
- **Nighttime awakenings**: 3-4 times/month
- **SABA use**: >2 days/week but not daily
- **Interference**: Minor limitation
- **Exacerbations**: ≥2/year requiring oral steroids
- **FEV1**: Normal (>80% predicted)

##### Moderate Persistent
- **Symptoms**: Daily
- **Nighttime awakenings**: >1 time/week but not nightly
- **SABA use**: Daily
- **Interference**: Some limitation
- **Exacerbations**: ≥2/year
- **FEV1**: 60-80% predicted

##### Severe Persistent
- **Symptoms**: Throughout the day
- **Nighttime awakenings**: Often 7 times/week
- **SABA use**: Several times per day
- **Interference**: Extremely limited
- **Exacerbations**: ≥2/year
- **FEV1**: <60% predicted

#### Management

##### Controller Medications (Daily Therapy)

###### Inhaled Corticosteroids (ICS)
- **First-line**: Most effective long-term control medication
- **Low dose**: Start dose for most patients
- **Medium/high dose**: Step up if inadequate control
- **Side effects**: Oral thrush, dysphonia (rinse mouth after use)
- **Growth**: Minimal effect on final adult height with low-medium doses

###### Long-Acting Beta-Agonists (LABA)
- **Combination**: Never as monotherapy (black box warning)
- **ICS/LABA**: Single inhaler for convenience (fluticasone/salmeterol, budesonide/formoterol)
- **Step up**: Add to ICS if inadequate control

###### Leukotriene Receptor Antagonists (LTRA)
- **Montelukast**: Alternative to ICS or add-on therapy
- **Advantages**: Oral medication, once daily
- **Efficacy**: Less effective than ICS for most patients
- **Black box warning**: Neuropsychiatric effects

###### Other Controllers
- **Cromolyn**: Mast cell stabilizer, rarely used
- **Theophylline**: Narrow therapeutic window, rarely used
- **Biologics**: Omalizumab (anti-IgE), mepolizumab (anti-IL-5), dupilumab (anti-IL-4/13) for severe asthma

##### Reliever Medications (Rescue Therapy)

###### Short-Acting Beta-Agonists (SABA)
- **Albuterol**: Most commonly used
- **Dose**: 2-4 puffs every 4-6 hours as needed
- **Overuse**: >2 days/week indicates inadequate control
- **Tremor**: Common side effect

##### Stepwise Approach
- **Intermittent asthma**: SABA as needed only
- **Persistent asthma**: Daily controller medication
- **Step up**: If not controlled on current therapy (after 3 months)
- **Step down**: If well controlled for ≥3 months (reduce by one step)
- **Exacerbations**: May require temporary step up

#### Asthma Action Plan
- **Green zone**: Well-controlled, continue daily medications
- **Yellow zone**: Getting worse, increase SABA, may need oral steroids
- **Red zone**: Medical alert, use SABA, seek immediate care

#### Education
- **Inhaler technique**: Demonstrate and assess at each visit
- **Spacer use**: Improves delivery, especially in young children
- **Trigger avoidance**: Identify and minimize exposures
- **Medication adherence**: Address barriers
- **Self-management**: Recognize early warning signs

#### Prognosis
- **Many improve**: With age, especially mild intermittent asthma
- **Remission**: 30-50% in adolescence
- **Persistence**: More likely with severe asthma, atopy, female gender

### Croup (Laryngotracheobronchitis)

#### Overview
- **Viral illness**: Inflammation of larynx and trachea
- **Age**: 6 months to 3 years (peak at 2 years)
- **Season**: Fall and winter

#### Clinical Presentation
- **Barky cough**: "Seal-like" or "barking" cough
- **Stridor**: Inspiratory, worse at night
- **Hoarseness**: From laryngeal inflammation
- **Fever**: Usually low-grade
- **URI prodrome**: 1-2 days before croupy symptoms

#### Management
- **Dexamethasone**: 0.6 mg/kg PO/IM × 1 dose (all children with croup)
- **Racemic epinephrine**: Nebulized for moderate-severe (observe 2-4 hours after)
- **Cool mist**: Traditional but limited evidence
- **Supportive care**: Hydration, antipyretics

*See Pediatric Infectious Diseases chapter for detailed coverage*

### Bronchiolitis

#### Overview
- **Most common LRTI**: In infants
- **Peak age**: 2-6 months
- **Cause**: RSV (50-80%), rhinovirus, others
- **Season**: November through March (Northern Hemisphere)

#### Clinical Presentation
- **URI prodrome**: Rhinorrhea, cough, low-grade fever
- **Progressive**: Worsening respiratory distress over 2-3 days
- **Wheezing**: Diffuse bilateral wheeze and crackles
- **Tachypnea**: Respiratory rate >60
- **Feeding difficulties**: Due to tachypnea
- **Hypoxemia**: In moderate-severe cases

#### Management
- **Supportive care only**: Mainstay of treatment
- **Hydration**: Oral or IV fluids
- **Oxygen**: If SpO2 <90%
- **Nasal suctioning**: For comfort
- **Not effective**: Bronchodilators, corticosteroids, antibiotics (unless secondary bacterial infection)

*See Pediatric Infectious Diseases chapter for detailed coverage*

## Gastrointestinal Conditions

### Gastroesophageal Reflux (GER) and GERD

#### Definitions
- **GER**: Physiologic reflux, asymptomatic
- **GERD**: Pathologic reflux with complications

#### Clinical Presentation

##### Infants
- **Spitting up**: Effortless regurgitation (GER, normal)
- **GERD features**: Poor weight gain, irritability, arching, apnea, feeding refusal
- **Sandifer syndrome**: Torticollis with reflux episodes

##### Older Children
- **Heartburn**: Burning in chest/epigastrium
- **Regurgitation**: Bitter taste in mouth
- **Chest pain**: May mimic cardiac pain
- **Dysphagia**: Difficulty swallowing

#### Diagnosis
- **Clinical**: Usually sufficient for infants and children
- **Upper GI series**: Anatomic evaluation, not diagnostic for GERD
- **pH probe**: Gold standard for acid reflux quantification
- **Endoscopy**: Evaluate for esophagitis, complications

#### Management

##### Lifestyle Modifications
- **Infants**:
  - Smaller, more frequent feeds
  - Upright positioning after feeds (30 minutes)
  - Thickened feeds (oatmeal cereal) - may help
  - Avoid overfeeding
- **Older children**:
  - Avoid trigger foods (fatty, spicy, acidic)
  - Weight loss if obese
  - Elevate head of bed
  - Avoid eating before bedtime

##### Medications

###### H2 Receptor Antagonists
- **Ranitidine**: Removed from market (NDMA contamination)
- **Famotidine**: 1 mg/kg/day divided BID
- **Efficacy**: Moderate for symptom relief

###### Proton Pump Inhibitors (PPIs)
- **Omeprazole, lansoprazole, esomeprazole**
- **Indications**: Erosive esophagitis, failed H2RA therapy
- **Concerns**: Long-term use (fractures, infections)
- **Duration**: Use shortest effective duration

##### Surgical Intervention
- **Nissen fundoplication**: For severe refractory GERD
- **Indications**: Failure of medical therapy, aspiration, severe esophagitis

#### Prognosis
- **Most infants**: Resolve by 12-18 months as GI tract matures
- **Older children**: May require longer-term therapy

### Constipation

#### Definition
- **Functional constipation**: Infrequent, painful, or difficult bowel movements without organic cause

#### Epidemiology
- **Prevalence**: 3-5% of children
- **Peak ages**: Toilet training (2-4 years), school entry

#### Rome IV Criteria (Functional Constipation)
At least 2 of the following for ≥1 month (infants/toddlers) or ≥2 months (≥4 years):
- **≤2 defecations per week**
- **History of excessive stool retention**
- **Painful or hard bowel movements**
- **Large diameter stools** (that may obstruct toilet)
- **Palpable abdominal or rectal mass**
- **≥1 episode/week of incontinence** after toilet training

#### Etiology

##### Functional (95%)
- **Withholding**: Pain avoidance, lack of time
- **Dietary**: Low fiber, excessive milk/dairy
- **Behavioral**: Toilet training issues, school bathrooms

##### Organic (5%)
- **Anatomic**: Anal stenosis, anterior anus
- **Hirschsprung disease**: Absent ganglion cells
- **Spinal**: Spina bifida, tethered cord
- **Metabolic**: Hypothyroidism, hypercalcemia
- **Medications**: Opioids, anticholinergics

#### Evaluation
- **History**: Stool frequency, consistency, pain, withholding behaviors, diet
- **Physical exam**: Abdominal mass, anal inspection, rectal exam (if indicated)
- **Red flags**: Delayed meconium (>48 hours), failure to thrive, abdominal distension, anal anomalies

#### Management

##### Disimpaction (if impacted)
- **Oral**: Polyethylene glycol (PEG) 1-1.5 g/kg/day for 3-6 days
- **Rectal**: Glycerin suppositories (infants), enemas (older children) if oral not tolerated

##### Maintenance Therapy
- **PEG (MiraLAX)**: 0.5-1 g/kg/day (most commonly used)
- **Lactulose**: 1-3 mL/kg/day divided BID
- **Mineral oil**: Avoid in children <1 year (aspiration risk)
- **Senna**: Stimulant laxative for refractory cases
- **Duration**: Months to years, taper slowly

##### Behavioral Interventions
- **Toilet sitting**: After meals, 5-10 minutes
- **Positive reinforcement**: Sticker charts, rewards
- **Avoid punishment**: Creates negative associations

##### Dietary Changes
- **Increase fiber**: Age + 5 grams/day
- **Adequate fluids**: Water throughout day
- **Limit cow's milk**: <24 oz/day

#### Prognosis
- **Resolution**: 50-70% within first year of treatment
- **Relapse**: Common if medication stopped too soon

### Acute Gastroenteritis

#### Overview
- **Common illness**: Leading cause of pediatric ED visits
- **Etiology**: Viral (most common), bacterial, parasitic
- **Complications**: Dehydration most concerning

#### Clinical Presentation
- **Diarrhea**: Increased frequency, decreased consistency
- **Vomiting**: Often preceding diarrhea
- **Abdominal pain**: Cramping
- **Fever**: Variable
- **Duration**: 3-7 days (viral)

#### Assessment of Dehydration

##### Mild (3-5% fluid loss)
- **Mucous membranes**: Slightly dry
- **Tears**: Present
- **Urine output**: Slightly decreased
- **Behavior**: Thirsty, alert

##### Moderate (6-9% fluid loss)
- **Mucous membranes**: Dry
- **Tears**: Decreased
- **Eyes**: Sunken
- **Fontanelle**: Sunken (if open)
- **Skin turgor**: Tenting
- **Urine output**: Decreased
- **Behavior**: Irritable

##### Severe (≥10% fluid loss)
- **Mucous membranes**: Very dry
- **Tears**: Absent
- **Eyes**: Deeply sunken
- **Extremities**: Cool, mottled
- **Capillary refill**: Prolonged (>3 seconds)
- **Pulse**: Weak, rapid
- **Blood pressure**: Low (late finding)
- **Mental status**: Lethargic

#### Management

##### Oral Rehydration Therapy (ORT)
- **First-line**: For mild-moderate dehydration
- **ORS composition**: Glucose-electrolyte solution (Pedialyte)
- **Rehydration phase**: 50-100 mL/kg over 3-4 hours
- **Maintenance phase**: Continue ORS, resume normal diet
- **Frequency**: Small amounts frequently (every 5-10 minutes)

##### IV Rehydration
- **Indications**: Severe dehydration, shock, intractable vomiting, neurologic compromise
- **Bolus**: 20 mL/kg NS or LR over 20-30 minutes (repeat as needed)
- **Maintenance**: Calculate deficit + maintenance + ongoing losses

##### Medications
- **Ondansetron**: May reduce vomiting, facilitate ORT (4 mg <15 kg, 8 mg ≥15 kg)
- **Probiotics**: May slightly reduce duration
- **Avoid**: Antidiarrheals (loperamide) - not recommended in children

##### Feeding
- **Continue regular diet**: As tolerated (no BRAT diet)
- **Breastfeeding**: Continue throughout illness
- **Formula**: Full-strength, no dilution needed

*See Pediatric Infectious Diseases chapter for pathogen-specific details*

## Dermatologic Conditions

### Atopic Dermatitis (Eczema)

#### Overview
- **Prevalence**: 10-20% of children
- **Onset**: Usually before age 5 (60% in first year)
- **Atopic triad**: Eczema, allergic rhinitis, asthma

#### Pathophysiology
- **Skin barrier dysfunction**: Filaggrin mutations, increased TEWL
- **Immune dysregulation**: Th2 predominance
- **Infection**: Staph colonization (90% of lesions)

#### Clinical Presentation

##### Age-Specific Distribution
- **Infants (<2 years)**: Face (cheeks), scalp, extensor surfaces
- **Children (2-12 years)**: Flexural areas (antecubital, popliteal), neck, wrists, ankles
- **Adolescents**: Hands, feet, face, neck, flexural areas

##### Features
- **Pruritus**: Intense itching (cardinal symptom)
- **Eczematous lesions**: Erythema, scaling, vesicles (acute), lichenification (chronic)
- **Xerosis**: Dry skin
- **Secondary changes**: Excoriations, crusting, hyperpigmentation

##### Diagnostic Criteria (Hanifin and Rajka)
- **Must have**: Pruritus
- **Plus ≥3 major**: Typical morphology and distribution, chronic/relapsing course, personal/family history of atopy, elevated IgE
- **Plus ≥3 minor**: Various including early age of onset, xerosis, Dennie-Morgan folds, keratosis pilaris

#### Management

##### Skin Care
- **Moisturize**: Frequently (at least BID), immediately after bathing
- **Bathing**: Short (5-10 min), lukewarm water, mild soap
- **Avoid triggers**: Harsh soaps, fragrances, wool, extremes of temperature

##### Topical Corticosteroids
- **First-line**: Anti-inflammatory treatment
- **Potency**: Low (face, intertriginous), medium-high (body, thickened areas)
- **Frequency**: Once to twice daily
- **Duration**: Short courses during flares
- **Side effects**: Skin atrophy, striae with prolonged use

##### Topical Calcineurin Inhibitors
- **Tacrolimus, pimecrolimus**: Steroid-sparing agents
- **Indications**: Face, eyelids, sensitive areas
- **Black box warning**: Theoretical cancer risk (not confirmed in studies)
- **Burning**: Common initially, improves with use

##### Other Therapies
- **Crisaborole**: PDE4 inhibitor (mild-moderate eczema)
- **Wet wrap therapy**: For severe flares
- **Phototherapy**: Moderate-severe, older children
- **Systemic immunosuppression**: Severe refractory (cyclosporine, methotrexate)
- **Biologics**: Dupilumab for severe eczema (age ≥6 months)

##### Infection Management
- **Bacterial**: Mupirocin, oral antibiotics for extensive impetigo
- **Bleach baths**: ½ cup bleach in full tub, 5-10 minutes, 2-3 times/week
- **Eczema herpeticum**: Disseminated HSV, requires IV acyclovir (medical emergency)

#### Prognosis
- **Remission**: 70% by adolescence
- **Persistence**: More likely with severe disease, early onset, family history

### Diaper Dermatitis

#### Types

##### Irritant Contact Dermatitis
- **Most common**: Prolonged exposure to urine/feces
- **Distribution**: Convex surfaces (spares creases)
- **Appearance**: Erythema, scaling

##### Candida Dermatitis
- **Risk factors**: Antibiotic use, prolonged moisture
- **Distribution**: Involves creases (satellite lesions)
- **Appearance**: Beefy red, well-demarcated, satellite papules/pustules

##### Other
- **Seborrheic**: Greasy, yellow scales
- **Allergic**: From wipes, creams (specific distribution pattern)

#### Management
- **Frequent changes**: Change diapers promptly when wet/soiled
- **Gentle cleansing**: Water or mild wipes, pat dry
- **Barrier cream**: Zinc oxide, petroleum jelly with each change
- **Air exposure**: Diaper-free time
- **Candida**: Topical antifungal (nystatin, clotrimazole)
- **Severe irritant**: Low-potency topical steroid short-term

## Hematologic Conditions

### Iron Deficiency Anemia

#### Epidemiology
- **Most common nutritional deficiency**: Worldwide
- **Peak age**: 9-24 months, adolescent females

#### Etiology
- **Inadequate intake**: Excessive cow's milk, poor diet
- **Increased demand**: Rapid growth (infancy, adolescence), menstruation
- **Decreased absorption**: Celiac disease, H. pylori
- **Blood loss**: GI bleeding, heavy menses

#### Clinical Presentation
- **Often asymptomatic**: Especially if gradual onset
- **Pallor**: Conjunctival, palmar
- **Fatigue**: Exercise intolerance
- **Pica**: Craving for ice, dirt, starch
- **Developmental**: Cognitive delays if severe/prolonged
- **Koilonychia**: Spoon nails (severe, chronic)

#### Diagnosis
- **CBC**: Microcytic (low MCV), hypochromic (low MCH) anemia
- **Iron studies**:
  - Low ferritin (best single test, <15 ng/mL diagnostic)
  - Low serum iron
  - High TIBC (>400)
  - Low transferrin saturation (<15%)
- **RDW**: Elevated (anisocytosis)
- **Reticulocyte count**: Low or normal (inappropriately low for anemia)

#### Management
- **Elemental iron**: 3-6 mg/kg/day divided (maximum 150-200 mg/day)
- **Formulation**: Ferrous sulfate most common
- **Timing**: Between meals (better absorption), with vitamin C
- **Duration**: 3 months after Hgb normalizes (to replete stores)
- **Response**: Reticulocytosis in 5-10 days, Hgb increase in 2-4 weeks
- **Side effects**: Constipation, dark stools, nausea (dose-related)

##### Dietary Counseling
- **Limit cow's milk**: <24 oz/day
- **Iron-rich foods**: Red meat, beans, iron-fortified cereals, dark leafy greens
- **Vitamin C**: Enhances absorption
- **Avoid**: Tea, calcium with iron-rich meals (inhibit absorption)

#### Follow-Up
- **Recheck CBC**: 4 weeks after starting treatment
- **If no response**: Consider non-compliance, ongoing losses, alternative diagnosis
- **Screen**: 9-12 months (all infants), high-risk adolescents

### Sickle Cell Disease

#### Overview
- **Genetic**: Autosomal recessive, HbS mutation
- **Types**: HbSS (most severe), HbSC, HbS-β thalassemia
- **Prevalence**: 1 in 365 African American births

#### Pathophysiology
- **HbS polymerization**: Deoxygenated state causes sickling
- **Vaso-occlusion**: Sickled cells obstruct microvasculature
- **Hemolysis**: Shortened RBC lifespan (10-20 days vs. 120)
- **Organ damage**: Chronic ischemia and infarction

#### Clinical Manifestations

##### Acute Complications

###### Vaso-Occlusive Crisis (Pain Crisis)
- **Most common**: Acute complication
- **Triggers**: Infection, dehydration, cold, stress, hypoxia
- **Pain**: Bones, joints, abdomen, chest
- **Duration**: Hours to days
- **Management**: Hydration, analgesia (opioids often needed), treat underlying cause

###### Acute Chest Syndrome
- **Second leading cause of hospitalization**
- **Presentation**: Fever, cough, chest pain, tachypnea, hypoxia
- **Chest x-ray**: New infiltrate
- **Etiology**: Infection, fat embolism, infarction
- **Management**: Antibiotics (cover atypical), transfusion, bronchodilators, oxygen
- **Complications**: Respiratory failure, leading cause of death

###### Splenic Sequestration
- **Age**: Infants and young children
- **Presentation**: Sudden splenomegaly, severe anemia, hypovolemia
- **Life-threatening**: Rapid circulatory collapse
- **Management**: Emergent transfusion
- **Recurrence**: Common, consider splenectomy after second episode

###### Stroke
- **Prevalence**: 10% by age 20 without screening/prophylaxis
- **Types**: Ischemic (children), hemorrhagic (adults)
- **Screening**: TCD ultrasound annually (age 2-16)
- **Prevention**: Chronic transfusion if high-risk
- **Acute management**: Emergent exchange transfusion

##### Chronic Complications
- **Functional asplenia**: Auto-splenectomy by age 5
- **Infection susceptibility**: Encapsulated organisms (Strep pneumo, H. flu, Neisseria)
- **Avascular necrosis**: Hip, shoulder
- **Retinopathy**: Proliferative retinopathy
- **Pulmonary hypertension**: Leading cause of death in adults
- **Chronic kidney disease**: Glomerular and tubular dysfunction
- **Leg ulcers**: Chronic wounds, difficult to heal

#### Diagnosis
- **Newborn screening**: All states screen
- **Hemoglobin electrophoresis**: Definitive diagnosis
- **CBC**: Anemia (Hgb 6-10), reticulocytosis, low MCV not characteristic

#### Management

##### Preventive Care
- **Penicillin prophylaxis**: Start at 2 months, continue until at least age 5
- **Immunizations**: All routine vaccines plus:
  - Pneumococcal (PCV13, PPSV23)
  - Meningococcal (quadrivalent and B)
  - Influenza (annual)
  - Haemophilus influenzae type b
- **Hydroxyurea**: Increases HbF, reduces crises, indicated for most patients
- **Folic acid**: 1 mg daily (increased demands from hemolysis)
- **TCD screening**: Annual ages 2-16

##### Disease-Modifying Therapies
- **Hydroxyurea**: First-line for HbSS, HbSβ⁰ thalassemia
- **Chronic transfusion**: Stroke prevention/secondary prevention, recurrent ACS
- **Crizanlizumab**: P-selectin inhibitor, reduces crises
- **L-glutamine**: May reduce crises
- **Voxelotor**: Increases Hgb, reduces hemolysis
- **Stem cell transplant**: Curative, for severe disease with matched donor
- **Gene therapy**: Emerging curative option

##### Acute Management
- **Fever**: Urgent evaluation, empiric antibiotics (ceftriaxone)
- **Pain crisis**: Aggressive analgesia, hydration
- **Acute chest syndrome**: Antibiotics, transfusion, incentive spirometry

## Endocrine Conditions

### Type 1 Diabetes Mellitus

#### Overview
- **Autoimmune destruction**: Pancreatic beta cells
- **Prevalence**: 1 in 300-400 children in US
- **Peak ages**: 5-7 years, puberty

#### Pathophysiology
- **Absolute insulin deficiency**: Loss of beta cell mass
- **Genetic susceptibility**: HLA-DR3, DR4
- **Environmental triggers**: Viral infections, diet (theories)

#### Clinical Presentation

##### Typical
- **Polyuria**: Osmotic diuresis from hyperglycemia
- **Polydipsia**: Compensatory fluid intake
- **Polyphagia**: Cellular starvation despite hyperglycemia
- **Weight loss**: Catabolism of fat and muscle
- **Enuresis**: New-onset bedwetting
- **Fatigue**: Cellular energy deficit

##### Diabetic Ketoacidosis (DKA)
- **25-40%**: Present in DKA at diagnosis
- **Symptoms**: Nausea, vomiting, abdominal pain, altered mental status
- **Kussmaul breathing**: Deep, labored respirations
- **Fruity odor**: Acetone on breath
- **Dehydration**: Severe in many cases

#### Diagnosis
- **Fasting glucose**: ≥126 mg/dL on two occasions
- **Random glucose**: ≥200 mg/dL with symptoms
- **HbA1c**: ≥6.5% (not reliable in very young children)
- **Autoantibodies**: GAD, IA-2, insulin (support autoimmune etiology)

#### Management

##### Insulin Therapy
- **Basal-bolus regimen**: Long-acting (glargine, detemir) + rapid-acting (lispro, aspart, glulisine)
- **Insulin pump**: Continuous subcutaneous insulin infusion
- **Dosing**: Typically 0.5-1 unit/kg/day (higher in adolescence)
- **Carbohydrate counting**: Match insulin to carb intake
- **Correction doses**: For hyperglycemia

##### Monitoring
- **Blood glucose**: Before meals, bedtime, as needed (4-10 times/day)
- **Continuous glucose monitor (CGM)**: Real-time glucose trends
- **HbA1c**: Every 3 months (target <7.5% for most children)
- **Complications screening**: Annual (retinopathy, nephropathy, neuropathy after 5 years)

##### Targets
- **Preprandial glucose**: 90-130 mg/dL
- **Bedtime glucose**: 90-150 mg/dL
- **HbA1c**: <7.5% (individualize)
- **Time in range**: >70% (70-180 mg/dL)

##### Acute Complications

###### Hypoglycemia
- **Definition**: <70 mg/dL
- **Symptoms**: Shakiness, sweating, hunger, confusion, irritability
- **Severe**: Seizure, loss of consciousness
- **Treatment**: 15 grams fast-acting carbs (juice, glucose tablets), recheck in 15 min
- **Glucagon**: IM/SC for severe (unable to take PO)

###### Hyperglycemia
- **Causes**: Illness, missed insulin, pump malfunction
- **DKA risk**: Check ketones if glucose >250 mg/dL and ill
- **Management**: Correction insulin, hydration, monitor ketones

##### Sick Day Management
- **Never stop insulin**: Increased insulin needs during illness
- **Monitor frequently**: Glucose and ketones every 2-4 hours
- **Hydration**: Maintain fluid intake
- **Ketones**: If moderate-large, give extra insulin and fluids (may need ER)

##### Nutrition
- **Carbohydrate counting**: Match insulin to intake
- **Balanced diet**: Similar to healthy children
- **No sugar-free requirement**: Can include sweets with appropriate insulin

##### Psychosocial Support
- **Multidisciplinary team**: Endocrinologist, diabetes educator, dietitian, psychologist
- **School plan**: 504 plan for accommodations
- **Transition**: Gradual shift of responsibility from parents to child
- **Mental health**: Screen for diabetes distress, depression, eating disorders

### Hypothyroidism

#### Types

##### Congenital Hypothyroidism
- **Incidence**: 1 in 2,000-4,000 births
- **Causes**: Thyroid dysgenesis (most common), dyshormonogenesis, central
- **Newborn screening**: Universal in US, start treatment immediately if positive

##### Acquired Hypothyroidism
- **Hashimoto thyroiditis**: Autoimmune (most common acquired cause)
- **Peak age**: Adolescence
- **Female predominance**: 4-7:1

#### Clinical Presentation

##### Congenital (if not screened)
- **Prolonged jaundice**: Beyond 2 weeks
- **Feeding difficulties**: Poor feeding, constipation
- **Hypotonia**: Decreased tone
- **Umbilical hernia**: Persistent
- **Large fontanelles**: Delayed closure
- **Macroglossia**: Enlarged tongue
- **Hoarse cry**: Deep, hoarse

##### Acquired
- **Growth failure**: Decreased height velocity, delayed bone age
- **Weight gain**: Despite normal intake
- **Fatigue**: Lethargy, cold intolerance
- **Constipation**: Decreased GI motility
- **Delayed puberty**: Or menstrual irregularities
- **Goiter**: Thyroid enlargement (Hashimoto)
- **Dry skin**: Brittle hair
- **Academic decline**: Difficulty concentrating

#### Diagnosis
- **TSH**: Elevated (primary hypothyroidism)
- **Free T4**: Low
- **Thyroid antibodies**: Anti-TPO, anti-thyroglobulin (Hashimoto)
- **Bone age**: Delayed

#### Management
- **Levothyroxine**: Synthetic T4
- **Dosing**: Weight-based (higher per kg in young children)
  - Newborn: 10-15 mcg/kg/day
  - Infant: 6-8 mcg/kg/day
  - Child: 4-6 mcg/kg/day
  - Adolescent: 2-4 mcg/kg/day
- **Timing**: Morning, 30-60 minutes before breakfast
- **Monitoring**: TSH, free T4 every 4-6 weeks initially, then every 3-12 months when stable
- **Target TSH**: 0.5-2.0 mIU/L

## Neurologic Conditions

### Febrile Seizures

#### Overview
- **Most common childhood seizure**: 2-5% of children
- **Age**: 6 months to 5 years
- **Temperature**: ≥38°C (100.4°F)
- **Absence**: Of CNS infection, metabolic disorder, previous afebrile seizures

#### Classification

##### Simple Febrile Seizure
- **Duration**: <15 minutes
- **Generalized**: Tonic-clonic, not focal
- **Frequency**: Once in 24 hours
- **90%**: Of febrile seizures

##### Complex Febrile Seizure
- **Duration**: ≥15 minutes
- **Focal features**: Focal onset or post-ictal Todd paralysis
- **Recurrent**: >1 in 24 hours
- **10%**: Of febrile seizures

#### Evaluation
- **Identify fever source**: Focus on underlying infection
- **Lumbar puncture**: Consider if:
  - Age <12 months (especially <6 months)
  - Signs/symptoms of meningitis
  - Complex features
  - Recently treated with antibiotics (may mask meningitis)
- **EEG**: Not routinely indicated for simple febrile seizure
- **Neuroimaging**: Not routinely indicated for simple febrile seizure
- **Labs**: Based on clinical scenario (electrolytes if concerning history)

#### Management
- **Acute**: Usually over before arrival
- **Prolonged**: Benzodiazepine if ongoing (diazepam, lorazepam)
- **Treat fever**: Antipyretics for comfort (do not prevent recurrence)
- **Prophylaxis**: Not recommended (risks outweigh benefits)
- **Education**: Seizure first aid, fever management, reassurance

#### Prognosis
- **Recurrence**: 30-40% will have another febrile seizure
- **Epilepsy risk**: Slightly increased (1-2% vs. 0.5-1% general population)
- **Higher risk if**: Complex features, family history epilepsy, neurodevelopmental abnormalities
- **Development**: Normal neurodevelopmental outcomes

### Headaches

#### Classification

##### Primary Headaches
- **Migraine**: Most common primary headache in children
- **Tension-type**: Second most common
- **Cluster**: Rare in children

##### Secondary Headaches
- **Infection**: Sinusitis, viral illness, meningitis
- **Increased ICP**: Tumor, hydrocephalus, pseudotumor cerebri
- **Vascular**: Stroke, AVM
- **Trauma**: Concussion, intracranial hemorrhage
- **Other**: Medication overuse, hypertension

#### Migraine

##### Clinical Features
- **Unilateral**: In adolescents (bilateral common in young children)
- **Pulsating**: Throbbing quality
- **Moderate-severe intensity**: Limits activities
- **Aggravated by activity**: Physical activity worsens
- **Associated symptoms**: Nausea/vomiting, photophobia, phonophobia
- **Duration**: 1-72 hours (often shorter in children)
- **Relief with sleep**: Characteristic

##### Variants
- **Migraine with aura**: Visual, sensory, or motor symptoms preceding headache
- **Abdominal migraine**: Recurrent abdominal pain, nausea, vomiting (midline, dull)
- **Cyclic vomiting**: Episodes of vomiting separated by symptom-free intervals
- **Hemiplegic migraine**: With motor weakness (rare, genetic forms)

##### Evaluation
- **Detailed history**: Headache characteristics, frequency, triggers, family history
- **Examination**: Usually normal (including neurologic exam)
- **Headache diary**: Track patterns, triggers, response to treatment
- **Neuroimaging**: Not routinely indicated unless red flags

##### Red Flags Requiring Imaging
- **Sudden severe headache**: "Worst headache of life"
- **Awakening from sleep**: Especially with vomiting
- **Progressive worsening**: Increasing frequency/severity
- **Neurologic signs**: Abnormal exam, seizures
- **Age <3 years**: Concerning
- **Papilledema**: Fundoscopic findings
- **Change in pattern**: Significant change from baseline

##### Management

###### Acute Treatment
- **NSAIDs**: Ibuprofen 10 mg/kg (first-line)
- **Acetaminophen**: 15 mg/kg (alternative)
- **Triptans**: Age ≥6-12 years (varies by triptan)
  - Sumatriptan nasal spray (age ≥12)
  - Rizatriptan, zolmitriptan (age ≥6-12)
- **Antiemetics**: Ondansetron, metoclopramide

###### Preventive Treatment
- **Indications**: ≥4 headaches/month, significant disability, failure of acute treatment
- **Options**:
  - Cyproheptadine (young children)
  - Amitriptyline
  - Topiramate
  - Propranolol
  - Valproate (avoid in females of childbearing potential)
- **CGRP antibodies**: Emerging for adolescents
- **Duration**: 6-12 months, then taper

###### Non-Pharmacologic
- **Trigger avoidance**: Identify and avoid (irregular sleep, skipped meals, stress, certain foods)
- **Lifestyle**: Regular sleep, meals, exercise, hydration
- **Stress management**: Relaxation techniques, biofeedback, CBT
- **Screen time**: Limit excessive use

## Key Points

- Asthma is the most common chronic childhood disease; ICS are first-line controller therapy
- Bronchiolitis management is supportive only; bronchodilators and steroids are not effective
- Oral rehydration therapy is first-line for mild-moderate dehydration from gastroenteritis
- Functional constipation is most common cause; organic causes are rare but must be ruled out
- Atopic dermatitis management focuses on moisturization, trigger avoidance, and topical anti-inflammatory therapy
- Iron deficiency anemia is most common nutritional deficiency; excessive cow's milk is major cause in toddlers
- Sickle cell disease requires comprehensive preventive care including penicillin prophylaxis, immunizations, hydroxyurea
- Type 1 diabetes management requires intensive insulin therapy, frequent monitoring, and multidisciplinary support
- Simple febrile seizures have excellent prognosis; prophylactic anticonvulsants not indicated
- Migraine management includes acute treatment, preventive therapy if frequent, and lifestyle modifications
- Family education and shared decision-making are essential for successful management of chronic conditions
- Most common pediatric conditions are best managed in primary care with subspecialty referral for complex or refractory cases

## References

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023.
2. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and Management of Bronchiolitis. Pediatrics. 2006;118(4):1774-1793.
3. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Evaluation and Treatment of Constipation in Infants and Children: Recommendations of NASPGHAN. J Pediatr Gastroenterol Nutr. 2006;43(3):e1-e13.
4. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of Care for the Management of Atopic Dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
5. American Diabetes Association. Children and Adolescents: Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1):S258-S281.
